メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
安水 洋太
泌尿器科学
ウェブサイト
https://k-ris.keio.ac.jp/html/100005838_ja.html
h-index
1095
被引用数
18
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2008
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(78)
類似のプロファイル
(6)
フィンガープリント
Yota Yasumizuが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Prostate Cancer
100%
Prostatectomy
85%
Transitional Cell Carcinoma
57%
Neoplasm
50%
Kidney Metastasis
46%
Castration Resistant Prostate Cancer
44%
Prostate Specific Antigen
43%
Biochemical Recurrence
41%
Targeted Therapy
38%
Mucin 1
37%
Recurrent Disease
33%
Radiation Therapy
28%
Androgen Deprivation Therapy
28%
Adrenalectomy
28%
Clear Cell Renal Cell Carcinoma
28%
Overall Survival
24%
Biological Marker
22%
Robot-Assisted Prostatectomy
21%
Neutrophil
21%
Lymphocyte
19%
Hormone Therapy
19%
Multivariate Analysis
19%
Prostate Hypertrophy
18%
Oncoprotein
18%
Multiparametric Magnetic Resonance Imaging
18%
Progression Free Survival
16%
High Risk Population
16%
Malignant Neoplasm
15%
Pheochromocytoma
15%
Cushing Syndrome
15%
Pembrolizumab
15%
Magnetic Resonance Imaging
15%
Hazard Ratio
14%
Seminal Vesicle
14%
Fibroblast Growth Factor Receptor 3
14%
Survival Rate
13%
Retroperitoneal Lymph Node Dissection
13%
Pelvis
13%
Nephroureterectomy
12%
Lymph Node
12%
CD8 Antigen
11%
Cystectomy
11%
Cisplatin
11%
Recurrence Free Survival
10%
Lymphocele
10%
Neuroendocrine Differentiation
10%
Prognostic Factor
10%
Macrophage
10%
Brachytherapy
9%
Case-Control Study
9%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
65%
Prostate Cancer
58%
Kidney Metastasis
55%
Prostate Specific Antigen
46%
Transitional Cell Carcinoma
42%
Androgen
40%
Mucin 1
37%
Overall Survival
33%
Neoplasm
30%
Recurrent Disease
29%
Biochemical Recurrence
29%
Docetaxel
28%
Bladder Cancer
23%
Chemotherapy
22%
Cushing Syndrome
18%
Oncoprotein
18%
Renal Cell Carcinoma
14%
Thymidylate Synthase
13%
Malignant Neoplasm
13%
Biological Marker
13%
Dactolisib
13%
Cisplatin
12%
Androgen Receptor
11%
Tumor Growth
11%
Progression Free Survival
11%
Drug Resistance
10%
Pheochromocytoma
9%
Prostate Hypertrophy
9%
C Reactive Protein
9%
Dutasteride
9%
CYP17A1
9%
Oxytocin Receptor
9%
Pazopanib
9%
Gemcitabine
9%
Survival Prediction
9%
Case-Control Study
9%
Hemodialysis
9%
Pembrolizumab
9%
Carcinoma
9%
Paclitaxel
9%
Hormone Cancer Therapy
9%
Niraparib
9%
Cabazitaxel
9%
Pharmaceutical Care
9%
Tumor Suppressor Protein
9%
Small Cell Lung Cancer
9%
Ureter Tumor
9%
Circulating Tumor DNA
9%
Phosphatase
9%
Survival Rate
9%
Keyphrases
Castration-resistant Prostate Cancer
44%
Radical Prostatectomy
34%
Biochemical Recurrence
27%
Metastatic Renal Cell Carcinoma (mRCC)
24%
Urothelial Carcinoma
16%
Salvage Radiotherapy
13%
Prostate Cancer
12%
Prostate-specific Antigen
12%
Robot-assisted Laparoscopic Radical Prostatectomy
12%
Seminal Vesicle Invasion
12%
Androgen Deprivation Therapy
12%
Treatment Strategy
11%
Second-line Treatment
10%
Docetaxel Chemotherapy
9%
Multi-institutional Study
9%
Cancer Cases
9%
C-reactive Protein
9%
Cisplatin Resistance
9%
Online Treatment
9%
Targeted Therapy
9%
NuRD Complex
9%
Progress Management
9%
Cushing
9%
CYP17A1 Inhibition
9%
Focal Brachytherapy
9%
Multiparametric MRI (mpMRI)
9%
Poor Prognostic Factors
9%
PI3K-mTOR Inhibitors
9%
NVP-BEZ235
9%
Robot-assisted Radical Prostatectomy
9%
Subclinical Cushing's Syndrome
9%
Nephroureterectomy
9%
Response Predictors
9%
Paclitaxel Chemotherapy
9%
Adrenalectomy
9%
Xenograft Model
9%
Gemcitabine Chemotherapy
9%
CD8-positive T Cells
9%
Anti-PD-1 Therapy
9%
Orbital Metastasis
9%
Transurethral Enucleation with Bipolar
9%
Bipolar Transurethral Resection
9%
Congenital Mid-ureteral Stricture
9%
Long-term Prognosis
9%
Long-term Treatment
9%
Grade Group
9%
Classic Variant
9%
Risk Model
9%
Hemodialysis Patients
9%
Mucin 1 (MUC1)
9%
